Biotech startups in Basel, Switzerland
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Vaderis Therapeutics | Basel | Series B | $152.0M | 2026-08-11 |
| Windward Bio | Basel | Series B | $165.0M | 2026-05-04 |
| FoRx Therapeutics | Basel | Series A | $50.0M | 2025-12-18 |
| Noema Pharma | Basel | Series B | $147.2M | 2024-12-11 |
| Rhygaze | Basel | Series A | $86.0M | 2025-01-10 |
| Cimeio Therapeutics | Basel | Series A | $50.0M | 2022-04-13 |
| Scailyte | Basel | Series A | $1.8M | 2023-12-04 |
| Engimmune Therapeutics | Basel | Seed | $15.8M | 2022-05-03 |
8 rows of the CSV in 5 of its 18 columns.
- The 39 biotech startups in Basel, Switzerland have raised $2.0B in total.
- 7 of them closed their most recent round in the last 12 months, $519.9M combined.
- The largest of those rounds is Windward Bio's $165.0M Series B, dated May 2026.
- The most recent is Nouscom's $134.7M Series D on 19 October 2026.
- Venture Kick is an investor in 7 of them, more than any other fund.
- Health care is the most common other sector, with 35 companies (90%).
- 41% were founded in 2020 or later; the median founding year is 2019.
- The most common team size is 1 to 10 employees (51% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
26 of 39| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
| Rhygaze | Rhygaze develops a gene therapy that targets cone cells to restore vision in blinding diseases. | Biotech | Series A | $86.0M | 2025-01-10 | $97.3M | Google Ventures, F-Prime, ARCH Venture Partners +2 | 11 to 50 | 2024 |
| Noema Pharma | Noema Pharma develops therapies that treat disabling symptoms of brain and nervous system conditions. | Biotech | Series B | $147.2M | 2024-12-11 | $316.5M | Polaris Partners, Sofinnova Partners, Invus +2 | 11 to 50 | 2019 |
| Translation-X | Translation-X is a spin-off project developing novel therapeutics for autism spectrum disorders. | Biotech | Pre-seed | $177K | 2024-09-30 | Venture Kick | 1 to 10 | 2022 | |
| NXI Therapeutics | NXI Therapeutics develops immunosuppressive drugs for autoimmune diseases and organ transplantation. | Biotech | Pre-seed | $4.0M | 2024-06-18 | $4.0M | Venture Kick, Kickfund, Gebert Rüf Stiftung +1 | 1 to 10 | 2021 |
| Myria Biosciences | Myria Biosciences discovers natural product drugs using genetically engineered cells that produce them. | Biotech | Pre-seed | $1.9M | 2024-01-05 | $1.9M | Creator Fund | 1 to 10 | 2022 |
| Scailyte | Scailyte delivers precision medicine through single-cell science. | Artificial intelligence | Series A | $1.8M | 2023-12-04 | $15.6M | Venture Kick, Verve Ventures, Innosuisse +2 | 11 to 50 | 2017 |
| KetoSwiss | KetoSwiss is a Swiss biotech startup developing ketone body products to combat diseases. | Biotech | Seed | $800K | 2023-08-04 | $6.4M | R42 Group, Healthspan Capital, Baszucki Group | 1 to 10 | 2017 |
| Versameb | Versameb discovers and develops RNA-based drugs. | Biotech | Seed | $10.0M | 2023-06-14 | $28.1M | Bernina BioInvest | 11 to 50 | 2017 |
| Vector BioPharma | Vector BioPharma develops gene precision delivery technology to improve biologics. | Biotech | Series A | $30.0M | 2022-08-10 | $30.0M | Versant Ventures | 11 to 50 | 2021 |
| Engimmune Therapeutics | Engimmune Therapeutics engineers T cell receptor therapies and develops products based on its platform. | Biotech | Seed | $15.8M | 2022-05-03 | Novo Holdings, Kinled Holding, Pureos Bioventures +1 | 11 to 50 | 2021 | |
| Cimeio Therapeutics | Cimeio Therapeutics develops curative treatments for genetic diseases, blood cancers, and severe autoimmune disorders. | Biotech | Series A | $50.0M | 2022-04-13 | $50.0M | Versant Ventures | 11 to 50 | 2020 |
| Stromal Therapeutics | Stromal Therapeutics is a biotechnology spin-off from the Kantonsspital St.Gallen. | Biotech | Seed | $537K | 2022-01-28 | BaseLaunch | 1 to 10 | 2018 | |
| POLYNEURON | Polyneuron is a pharmaceutical company developing a new drug class for autoimmune disorders. | Biotech | Series A | $15.4M | 2020-09-16 | $45.0M | New Enterprise Associates, Venture Kick, Sofinnova Partners +1 | 1 to 10 | 2014 |
| Arvelle Therapeutics | Arvelle Therapeutics is a biopharmaceutical company developing medicines for patients. | Biotech | Series A | $42.7M | 2020-05-27 | KB Investment, F-Prime, EQT Life Sciences +2 | 51 to 100 | 2019 | |
| deepCDR Biologics | deepCDR Biologics is a biotechnology company providing scalable technologies and services. | Biotech | Pre-seed | $41K | 2020-01-21 | $82K | Venture Kick | 1 to 10 | 2019 |
| NBE-Therapeutics | NBE-Therapeutics develops oncology treatments for cancer patients. | Biotech | Series C | $22.0M | 2020-01-10 | $65.7M | Novo Holdings, Boehringer Ingelheim Venture Fund, PPF Group | 11 to 50 | 2012 |
| Therachon | Therachon is a global biotechnology company developing medicines for rare genetic diseases. | Biotech | Series B | $60.0M | 2018-08-09 | $100.0M | Bpifrance, New Enterprise Associates, OrbiMed +2 | 1 to 10 | 2014 |
| PIQUR Therapeutics | PIQUR Therapeutics is a Swiss pharmaceutical company developing anti-cancer drugs. | Biotech | Series A | $30.9M | 2017-09-01 | $86.9M | Venture Kick, Versant Ventures | 11 to 50 | 2011 |
| KORING | KORING develops innovations that improve quality of life for stoma patients worldwide. | Biotech | Pre-seed | $140K | 2013-01-28 | $140K | Venture Kick | 1 to 10 | 2012 |
| Synosia Therapeutics | Synosia Therapeutics develops and commercializes products for unmet needs in psychiatry and neurology. | Biotech | Series C | $30.0M | 2010-10-12 | $94.0M | Novo Holdings, Versant Ventures, 5AM Ventures +2 | 1 to 10 | 2006 |
| Okairos | Okairos develops genetic T-cell vaccines, including candidates targeting hepatitis C virus. | Biotech | Series B | $20.5M | 2010-09-14 | $30.1M | EQT Life Sciences, Versant Ventures, Novartis Venture Fund +2 | 1 to 10 | 2007 |
| Vivendy Therapeutics | Vivendy Therapeutics develops enzyme replacement therapies. | Biotech | Series B | $30.5M | 2008-06-23 | EQT Life Sciences, BioMedPartners, TVM Capital +1 | 11 to 50 | 2006 | |
| 4-Antibody AG | 4-Antibody AG develops a human antibody drug-discovery platform for immuno-oncology therapeutics. | Biotech | Series A | $18.4M | 2007-01-16 | $20.6M | EQT Life Sciences, BioMedPartners, Grazia Equity +2 | 251 to 500 | 2002 |
Table 1. Biotech startups in Basel, Switzerland: the 26 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 39.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| 2 | Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| 3 | FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
Table 2. Biotech startups in Basel, Switzerland: the 3 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Venture Kick | Startup incubator | Schlieren, Switzerland | 7 | 18% | ||
| 2 | Versant Ventures | Venture capital firm | Menlo Park, United States | 6 | 15% | ||
| 3 | Novo Holdings | Corporate venture arm | Hellerup, Denmark | 5 | 13% | 1 | Windward Bio |
| 4 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 5 | 13% | 1 | FoRx Therapeutics |
| 5 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 3 | 8% | 1 | FoRx Therapeutics |
| 6 | BaseLaunch | Startup accelerator | Allschwil, Switzerland | 3 | 8% | ||
| 7 | BioMedPartners | Venture capital firm | Basel, Switzerland | 3 | 8% | ||
| 8 | OrbiMed | Private equity firm | New York, United States | 2 | 5% | 1 | Windward Bio |
| 9 | Sofinnova Partners | Venture capital firm | Paris, France | 2 | 5% | ||
| 10 | F-Prime | Venture capital firm | Cambridge, United States | 2 | 5% | ||
| 11 | Boehringer Ingelheim Venture Fund | Corporate venture arm | Ingelheim Am Rhein, Germany | 2 | 5% | ||
| 12 | Gebert Rüf Stiftung | Entrepreneurship program | Basel, Switzerland | 2 | 5% | ||
| 13 | New Enterprise Associates | Venture capital firm | Menlo Park, United States | 2 | 5% | ||
| 14 | Medicxi | Venture capital firm | London, United Kingdom | 1 | 3% | 1 | Vaderis Therapeutics |
| 15 | Blue Owl | Private equity firm | New York, United States | 1 | 3% | 1 | Windward Bio |
Table 3. Biotech startups in Basel, Switzerland: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 35 | 90% | $1.9B |
| Artificial intelligence | 2 | 5% | $15.6M |
| Software | 1 | 3% | $15.6M |
Table 4. Biotech startups in Basel, Switzerland by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Pre-seed | 9 | 23% | $177K |
| Seed | 7 | 18% | $10.0M |
| Series A | 13 | 33% | $30.0M |
| Series B | 7 | 18% | $70.0M |
| Series C | 2 | 5% | $30.0M |
| Series D+ | 1 | 3% | $134.7M |
Table 5. Biotech startups in Basel, Switzerland by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 1 | 14% | $134.7M |
| August 2026 | 1 | 14% | $152.0M |
| June 2026 | 1 | 14% | |
| May 2026 | 1 | 14% | $165.0M |
| January 2026 | 1 | 14% | $12.5M |
| December 2025 | 2 | 29% | $55.7M |
Table 6. Biotech startups in Basel, Switzerland: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 5 | 13% | $464.2M |
| 2025 | 7 | 18% | $213.6M |
| 2024 | 4 | 10% | $153.2M |
| 2023 | 4 | 10% | $12.6M |
| 2022 | 4 | 10% | $96.4M |
| 2021 | 2 | 5% | $1.2M |
Table 7. Biotech startups in Basel, Switzerland by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 6 | 15% |
| 2020 to 2022 | 10 | 26% |
| 2015 to 2019 | 12 | 31% |
| 2010 to 2014 | 6 | 15% |
| Before 2010 | 5 | 13% |
Table 8. Biotech startups in Basel, Switzerland by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 20 | 51% |
| 11 to 50 | 17 | 44% |
| 51 to 100 | 1 | 3% |
| 251 to 500 | 1 | 3% |
Table 9. Biotech startups in Basel, Switzerland by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Basel, Switzerland. On 16 November 2026 that is 39 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 26 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 39 rows: 4 have no round amount, 0 no city and 9 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Basel, Switzerland are on the list?
- 39, in the file dated 16 November 2026. 7 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 39 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.